Pfizer Inc. (PFE) — closed signal from January 1, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on April 1, 2026 — +14.7% at the close.
Predicted vs. what happened
What happened
Reached its target in 41 days.
The thesis — published January 1, 2026
Pfizer looks like it's bouncing after a sharp selloff, and its dividend and recent headlines about modest price increases could make some buyers return. The stock is very oversold, so a short-term recovery is possible, but underlying trend remains weak and the rally might not hold. Treat this as a short-term, tight-risk trade over the next 0-3 months.
Primary drivers
- Very oversold can create quick bounce opportunities
- Dividend focus can draw safety-oriented buyers
- Small price hikes can improve investor mood short-term
- Recovery relies on improving buying momentum, not value change
How it played out
PFE: target reached in 41 days
Lyra published PFE at $24.90 on 2026-01-01, with a short-term window through 2026-04-01. The thesis expected 12% growth. It pointed to an oversold setup after a sharp selloff, dividend-focused buyers, modest price increases, and the need for better buying momentum.
Inside the window, PFE reached the $27.89 target in 41 days. The stock peaked at $28.64 on 2026-04-01, with a 15% peak gain. It ended at $28.55. The published bounce thesis played out.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.